InnoCare Pharma (SEHK:9969) Stock Dropped, So What Is Driving Attention Now?

Simply Wall St.10-08 23:35

InnoCare Pharma (SEHK:9969) drew fresh attention after announcing a research collaboration and license agreement with Eli Lilly to develop new medicines, including potential eligibility for up to US$...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2674042020?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","is_english":true,"pubTime":"2026-10-08 23:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2674042020","market":"hk","top_or_hot":-1,"title":"InnoCare Pharma (SEHK:9969) Stock Dropped, So What Is Driving Attention Now?","media":"Simply Wall St.","content":"<div>\n<p>InnoCare Pharma (SEHK:9969) drew fresh attention after announcing a research collaboration and license agreement with Eli Lilly to develop new medicines, including potential eligibility for up to US$...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-stock-dropped-so-what-is-driving-at\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InnoCare Pharma (SEHK:9969) Stock Dropped, So What Is Driving Attention Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnoCare Pharma (SEHK:9969) Stock Dropped, So What Is Driving Attention Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-08 23:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-stock-dropped-so-what-is-driving-at><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>InnoCare Pharma (SEHK:9969) drew fresh attention after announcing a research collaboration and license agreement with Eli Lilly to develop new medicines, including potential eligibility for up to US$...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-stock-dropped-so-what-is-driving-at\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-stock-dropped-so-what-is-driving-at","article_id":"2674042020","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-stock-dropped-so-what-is-driving-at","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2674042020","pubTimestamp":1791473706,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"InnoCare Pharma (SEHK:9969) drew fresh attention after announcing a research collaboration and license agreement with Eli Lilly to develop new medicines, including potential eligibility for up to US$3.35b in combined upfront and milestone payments.\nFor investors watching the tape, InnoCare Pharma’s share price has come under pressure, with a 7-day share price return down 15.21% and a 30-day share price return down 15.04%. At the same time, the 3-year total shareholder return remains up...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","09969":"诺诚健华"},"translate_title":"诺诚健华医药（SEHK:9969）股价下跌，那么现在是什么引起了人们的关注？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09969":0.9},"content_text":"InnoCare Pharma (SEHK:9969) drew fresh attention after announcing a research collaboration and license agreement with Eli Lilly to develop new medicines, including potential eligibility for up to US$3.35b in combined upfront and milestone payments. For investors watching the tape, InnoCare Pharma’s share price has come under pressure, with a 7-day share price return down 15.21% and a 30-day share price return down 15.04%. At the same time, the 3-year total shareholder return remains up 99.68%, suggesting that recent weakness contrasts with a much stronger longer-term journey. Scan how other biopharma stocks with research partnerships and licensing potential are setting up by reviewing the hand picked 618 high quality undiscovered gems alongside InnoCare Pharma. After a sharp pullback despite the Lilly deal, InnoCare Pharma now sits at a level where some investors consider edging in, while others prefer patience in hopes of an even cheaper entry. So how does the current valuation stack up? AdvertisementMost Popular Narrative: 36% Undervalued Against the last close at HK$12.54, the most widely followed narrative for InnoCare Pharma points to a fair value of HK$19.62. As a result, the recent pullback has only sharpened the gap implied by those long range assumptions.  The analysts have a consensus price target of HK$19.62 for InnoCare Pharma based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of HK$22.32, and the most bearish reporting a price target of just HK$17.0.  See why 1 investors see InnoCare Pharma as 36% undervalued. Result: Fair Value of HK$19.62 (UNDERVALUED) Still, the bullish InnoCare Pharma story can crack if high R&D spending fails to translate into successful launches or if key drugs lose ground to rival therapies. Find out about the key risks to this InnoCare Pharma narrative. Another View: InnoCare Pharma Looks Expensive On Earnings While the most popular narrative pegs InnoCare Pharma below fair value, the earnings multiple tells a different story. The stock trades on a P/E of 19.8x, compared with a fair ratio of 9.8x and a Hong Kong biotechs average of 17.7x. That premium suggests less margin for error if the growth story wobbles. For investors weighing which signal to trust, the question becomes whether this richer multiple is a warning sign or simply the price of exposure to InnoCare Pharma's pipeline. See what the numbers say about this price — find out in our valuation breakdown. SEHK:9969 P/E Ratio as at Oct 2026Next Steps Mixed signals on InnoCare Pharma so far. If you want to act decisively rather than follow the crowd, start by weighing both sides of the story through the 3 key rewards and 3 important warning signs. Looking for more investment ideas beyond InnoCare Pharma? If you stop at InnoCare Pharma, you miss a wider field of opportunities. Broaden your watchlist using targeted screeners that surface very different types of potential.  Zero in on potential deep value by reviewing the 186 high quality undervalued stocks that combine quality fundamentals with prices some investors see as out of sync. Lock in potential income ideas by scanning the 225 dividend fortresses that focus on companies offering higher yields alongside established payout records. Dial down portfolio stress by filtering for the 225 resilient stocks with low risk scores that prioritize financial resilience and more measured volatility profiles.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2674042020","isCrawlerRequest":true}